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Serotonin metabolism in rat mesangial cells: Involvement of a role in the regulation of glomerular filtration rate [1]
serotonin transporter and monoamine oxidase A. and participate in the development of functional and
Background. Serotonin is one of the factors regulating mes- morphological glomerular abnormalities in inflamma-angial cell proliferation, and convergent evidence supports its
tory processes [2]. The function of MCs is regulatedinvolvement in the development of glomerulonephritis. In this
by a variety of mediators, including biogenic amines,study, we identified a serotonin transporter and the amine-
degrading enzyme monoamine oxidases (MAOs) in mesangial angiotensin II, bradykinin, growth factors, and cytokines
cells, and we studied their involvement in serotonin degrada- [3]. Some of these factors, including dopamine [4], angio-
tion. tensin II [5], bradykinin [6], and serotonin [7], are mostlyMethods. MAOs were characterized in membrane prepara-
involved in MC contraction. Moreover, serotonin [8],tions and intact mesangial cells by enzyme assay using [14C]5-
cytokines, and growth factors [9] play a particularly im-hydroxytryptamine and [14C]b-phenylethylamine as specific
substrates for MAO-A and MAO-B, respectively, and by West- portant role in the modification of MC function occurring
ern blot analysis. The expression of a serotonin transporter was in glomerulonephritis.
determined by [14C]5-hydroxytryptamine uptake experiments
Several studies showed that serotonin is a potent mito-and Western blot. Mesangial cell proliferation was measured
gen factor of MCs [7, 10, 11], and this mitogen activityby BrdU incorporation.
Results. Quantitation of the MAO isoforms by enzyme assay may participate in the development of glomerulonephri-
and Western blot analysis showed that MAO-A was largely tis. Part of the serotonin mitogen activity is related to a
predominant in mesangial cells, accounting for approximately receptor-mediated second-messenger generation [12]. In
90% of the total enzyme population. The MAO substrate
addition, it has been recently suggested that part of the[14C]serotonin was transported into mesangial cells by a satura-
effect on cell proliferation requires serotonin uptake intoble uptake system (Vmax 310 6 36 pmol/30 min/mg protein; Km
5.9 6 1.4 mm) displaying the pharmacological properties of a the cells and, therefore, could occur independently of
serotonin transporter. The expression of a serotonin trans- membrane receptor stimulation [13, 14]. Most of the
porter was confirmed by Western blot analysis. MAO activity serotonin acting on MCs is released by platelets infiltrat-measured in intact cells showed that after accumulation into
ing the site of glomerular injury. Recent studies showedmesangial cells, [14C]serotonin was metabolized by MAO-A.
that serotonin can be produced by the renal proximalFinally, serotonin-mediated mesangial cell proliferation was
significantly increased after irreversible MAO inhibition. tubule and secreted at the basolateral side, where it acts
Conclusions. Our results suggest that serotonin concentra- as an autocrine factor [15]. It is conceivable that part of
tion and function in glomeruli may be regulated in part by its the serotonin released from the proximal tubule maytransport into mesangial cells and degradation by MAO-A.
reach the glomerulus to regulate MC activities under
physiological conditions.
Extracellular availability of biogenic amines (that is,Mesangial cells (MCs) are a major constituent of renal
serotonin, norepinephrine, epinephrine, and dopamine)glomerulus. These smooth muscle-like cells play a critical
depends in part on their degradation rate by the mito-
chondrial enzyme monoamine oxidases (MAOs) [16, 17].
Currently, two MAO isoforms, encoded by separateKey words: serotonin transporter, monoamine oxidase, mesangial cells,
cell proliferation, glomerulonephritis, transport. genes sharing a common intron/exon organization [18],
have been identified based on substrate specificity:Received for publication December 1, 1998
MAO-A preferentially metabolizes serotonin and ky-and in revised form April 22, 1999
Accepted for publication May 19, 1999 nuramine, whereas MAO-B has a greater affinity for
phenylethylamine and benzylamine [19]. The two MAO 1999 by the International Society of Nephrology
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isoforms can be also differentiated according to their (unlike endothelial cells), (d) the ability to grow on
d-valine–containing medium (unlike fibroblasts), (e)inhibition by synthetic compounds: clorgyline and moc-
lobemide for MAO-A and selegiline and lazabemide for positive staining with anti–Thy1-1 antibody, ( f) the pres-
ence of actin filament revealed by NBD-phallacidin, (g)MAO-B [20]. Several studies showed that the kidney
contains one of the highest MAO activities of the body the presence of a smooth muscle actin (a-SMA). The
expression of a-SMA received much attention. Because[21, 22]. Although both MAO-A and MAO-B have been
identified in cortex and medulla, their precise localiza- a-SMA is not expressed in vivo as well as in three-
dimensional culture but is expressed in MCs under nor-tion in the different portions of the nephron has not
been investigated with the exception to the proximal mal development and in experimental and human glo-
merular diseases, the expression of a-SMA is consideredtubule [23, 24].
As MAO are mitochondrial enzymes, serotonin needs a marker of MC activation. Under our basal conditions,
MC expressed a-SMA and serum deprivation for 48to be transported into the cells to be metabolized. The
mechanism of intracellular serotonin transport has been hours, which is the maximum time tested, did not change
the expression of the protein as assessed by immunoflu-extensively investigated in the central nervous system.
In presynaptic terminals and glial cells [25], serotonin orescence. Moreover, within the number of passages
used (between passages 4 through 7) in our experiments,uptake is mediated by a specific serotonin transporter
(SERT). This transporter, which in human and rat con- the doubling time of the cell cycle remained unchanged.
tains 630 amino acids, displays a very low affinity for
Amine oxidase activityother biogenic amines (for example, norepinephrine and
dopamine) and is selectively inhibited by the antidepres- Monoamine oxidase activity was measured by the
slightly modified method of Yu [32]. Cells were harvestedsive drugs clomipramine and fluoxetine [26–28]. Several
studies have shown that the SERT is also expressed in in sodium phosphate buffer (50 mm, pH 7.4), supple-
mented by protease inhibitors (0.1 mm phenylmethylsul-peripheral organs such as lung, placenta [29], and adrenal
medulla [25, 30], where it seems to regulate serotonin fonyl fluoride, 10 mg/ml bacitracin, and 2 mg/ml soybean
trypsin inhibitor). Crude extracts of rat MCs were incu-clearance. Currently, the expression of a SERT in the
kidney has not been reported. bated at 378C for 20 minutes in a final volume of 250 ml
of sodium phosphate buffer with a required concentra-In this study, using different approaches, we show, for
the first time, that MCs contain under normal culture tion of [14C]5-hydroxytryptamine (25 to 400 mm) or
[14C]b-phenylethylamine ([14C]PEA; 0.75 to 160 mm) asconditions a functional SERT and the serotonin-metabo-
lizing enzyme MAO-A. In addition, we demonstrate that specific substrate for MAO-A and MAO-B, respectively.
Pargyline (1025 m) was used to measure nonspecificserotonin-mediated MC proliferation was significantly
increased after irreversible MAO inhibition. These data MAO activities. The protein content varied between 100
and 200 mg/assay tube. After 20 minutes, the reactionssuggest that SERT and MAO-A may be one of the fac-
tors regulating the serotonin level and its functional ac- were stopped by adding 1 ml of 2 m HCl and 2 ml of
extraction solvent (toluene/ethyl acetate vol/vol). Aftertivity in mesangium.
vigorous mixing and centrifugation, 1 ml aliquot of the
organic phase was counted in a liquid scintillation
METHODS
counter (Packard 1900 TR; Packard Instruments, Meri-
Cell culture den, CT, USA). MAO activity was expressed as pmol
of oxidized substrate during one minute of incubationRat MCs were isolated and cultured as described pre-
viously by Edmond et al [31]. Briefly, primary MCs were per milligram of protein.
obtained as outgrowths of collagenase-digested glomer-
Western blot analysesuli. Glomerular explants were allowed to grow to con-
fluence in RPMI supplemented with 1 mm sodium pyr- Homogenate extracts were solubilized in loading
buffer [60 mm Tris-HCl, pH 6.8, containing 2% sodiumuvate, 100 units of penicillin, 100 mg/ml streptomycin,
and 15% fetal calf serum (FCS). Cells were used three dodecyl sulfate (SDS), 10% glycerol, 1% b-mercapto-
ethanol, and 0.05% bromophenol blue] at 1008C for fiveweeks after the beginning of culture or were treated with
trypsin/ethylenediaminetetraacetic acid (EDTA) and minutes and subjected to 9% SDS-polyacrylamide gel
electrophoresis. Proteins were transferred to polyvinyli-transferred to new culture dishes in the same complete
medium. All experiments were performed using conflu- dene difluoride membranes with a semidry electroblotter
(Trans-blot; Bio-Rad, Richmond, CA, USA) for oneent primary cells and cells from passages four through
seven. Cells were identified as MCs according to the hour at 450 mA. The blots were saturated with 5% nonfat
dried milk for MAO immunoblot or with 0.1% casein forfollowing criteria, as previously described [31]: (a) spin-
dle shaped morphology, (b) resistance to puromycin (un- SERT immunoblot in wash buffer [phosphate-buffered
saline (PBS), pH 7.5 (Dulbecco, Seromed), and 0.1%like epithelial cells), (c) negative staining for factor VIII
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Tween 20) overnight at 48C. Then the blots were washed incubated for 20 hours with indicated concentrations of
5HT with or without pargyline in RPMI 0.5% FCS. BrdUtwice and incubated for one hour at room temperature
with a rabbit polyclonal antisera to MAO-A and MAO-B was added during four hours. Cells were harvested, and
cellular proliferation was assessed by BrdU incorpora-[31] or a goat polyclonal antisera directed against SERT
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). The tion using a colorimetric immunoassay (Biotrak; Amer-
sham).rabbit polyclonal antisera were obtained by immuniza-
tion with the peptide TNGGQERKFVGGSGQ corre-
Protein determinationsponding to amino acids 211 to 225 in MAO-A and 202
to 216 in MAO-B. After washing, blots were incubated Proteins were measured by BioRad assay (BioRad,
Ivry/Seine, France) using g-globulins as the standard.with peroxidase-labeled antirabbit or antigoat for 40
minutes. Bound antibodies were detected using en-
Statistical analysishanced chemiluminescence (Amersham Life Sciences,
Arlington Heights, IL, USA) and exposure to Amer- Monoamine oxidase and serotonin transport steady-
state kinetic parameters, IC50 of inhibition of enzymesham Hyperfilme-MP film. Immunoreactive proteins
were quantitated using an ImageQuant Software (Molec- activity, and IC50 of inhibition of serotonin transport were
evaluated using nonlinear square curve-fitting proce-ular Dynamics, Sunnyvale, CA, USA).
dures (Prisme; GraphPad, San Diego, CA, USA). The
[14C]serotonin uptake and metabolism in statistical comparison of the results was obtained by using
mesangial cells one-way analysis of variance followed by the Newman-
Keuls multiple comparison test as well as the Student’sCells were preincubated at 378C for 20 minutes with
Hank’s buffer containing 1 mm l-ascorbic acid and with unpaired t-test. Results are expressed as means 6 sem.
or without 10 mm of pargyline to inhibit MAOs. Subse-
Materialsquently, the cells were incubated with an increasing
[14C]5 hydroxytryptamine ([14C]5HT) concentration (100 [14C]serotonin (57.8 Ci/mol), [14C]b-phenyletylamine
(57 Ci/mol), and polyvinylidene difluoride membranesnm to 10 mm). Specific uptake was defined as the fraction
of total uptake inhibited by 10 mm of clomipramine and were purchased from DuPont NEN (Le Blanc Mesnil,
France). SERT antibodies were purchased from Santawas expressed as pmol of [14C]5HT accumulated per mg
of protein during 1 or 30 minutes of incubation. Trans- Cruz Biotechnology (Santa Cruz, CA, USA). Acryl-
amide, bisacrylamide, and Tween 20 were purchasedport inhibitors were present during the preincubation
and incubation period. At the end of incubation, the from Bio-Rad. Clomipramine was provided by Research
Biochemichals Int. (Natick, MA, USA). Fluoxetine wasmedium was removed to measure extracellular serotonin
metabolites. Cells were rinsed four times with 4 ml ice- purchased from Tocris Cookson (Bristol, UK). Dispro-
cynium 24 was a generous gift from Dr. Edgard Schomı¨gcold Hank’s buffer and were then solubilized with 5 mm
Tris-HCl, 0.1% Triton X-100, pH 7.4. Radioactivity (Heidelberg, Germany). All remaining drugs and chemi-
cals were purchased from Sigma (Paris, France).was measured by liquid scintillation counting (Packard
1900 TR).
Serotonin metabolism in intact cells was evaluated
RESULTS
by the concomitant measure of intracellular [14C]5HT
Monoamine oxidase-A and monoamine oxidase-Baccumulation and the extracellular release of [14C]5HT
activity in rat mesangial cellsmetabolites. Uptake experiments were performed as de-
scribed earlier in this article without irreversible MAO Monoamine oxidases were identified and character-
ized by enzyme assay using [14C]5HT and [14C]PEA asinhibition. Extracellular [14C]5HT metabolites produced
by MAOs were measured by an adaptation of the origi- substrates for MAO-A and MAO-B, respectively, as well
as by Western blot analysis. Velocity versus substratenal method described by Wurtman and Axelrod [33].
Briefly, metabolites were extracted from extracellular concentration experiments showed that MCs oxidized
both [14C]5HT (Vmax 95 6 17 pmol/min/mg protein; Kmincubation medium by 2 ml of toluene/ethyl acetate (vol/
vol). After vigorous mixing, a 1 ml aliquot of extraction 67 6 7 mm) and [14C]PEA (Vmax 51 6 3 pmol/min/mg
protein; Km 46 6 7 mm; Fig. 1). Inhibition of enzymesolvent was counted in a liquid scintillation counter
(Packard 1900 TR). activities using subtype selective MAO inhibitors show-
ed that, as expected, [14C]5HT oxidation was inhibited
BrdU incorporation by the MAO-A inhibitor clorgyline (IC50 0.2 6 0.05 nm),
and it was poorly affected by high concentrations of theRat MCs were used between passages 5 and 7. Cells
were seeded into 96-well microtiter plate in RPMI 15% MAO-B inhibitor selegiline (IC50 2.5 6 1 mm; Fig. 2A).
Studies on the inhibition of [14C]PEA oxidation suppliedFCS. After 48 hours, the growth medium was replaced
by RPMI without FCS during two hours. Cells were unexpected results. Indeed, the inhibition curve of
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Fig. 1. Concentration-dependent oxidation of
the monoamine oxidase (MAO) substrates
[14C]5HT (A) and [14C]PEA (B) in rat mesan-
gial cells. Cell extracts were incubated with
increasing concentrations of the appropriate
radioactive substrate. The curves represent
the specific enzyme activity, as defined by the
difference between the substrate oxidation
measured in the absence or presence of the
irreversible MAO inhibitor pargyline (1025 m).
The nonspecific activities represented 10 to
15% of the total substrate oxidation. Each
point represents the mean 6 sem of four prep-
arations.
Fig. 2. Inhibition of monoamine oxidase
(MAO) activity in rat mesangial cell extracts.
Crude extracts of mesangial cells were incu-
bated with [14C]5HT 100 mm (A) or [14C]PEA
20 mM (B) in the absence or presence of in-
creasing concentrations of clorgyline (MAO-A
inhibitor) (d) or selegiline (MAO-B inhibitor)
(,). Each point is the mean 6 sem of three
to seven preparations.
[14C]PEA oxidation by the MAO-B inhibitor selegiline
was biphasic, that is, only 15% of the enzyme activity
was inhibited by selegiline concentrations compatible
with those reported for inhibition of MAO-B. In con-
trast, the remaining 85% of [14C]PEA degradation was
poorly affected by selegiline and was inhibited by the
MAO-A inhibitor clorgiline with an IC50 close to that
observed for inhibition of [14C]5HT oxidation (Fig. 2B).
Western blot analysis of monoamine oxidase-A and
monoamine oxidase-B expressed in rat renal cortex Fig. 3. Western blot of rat renal cortex, mesangial cells, and glomeruli
using an anti–MAO-A/MAO-B antiserum. Crude homogenates fromand mesangial cells
renal cortex (30 mg), mesangial cells (50 mg), and glomeruli (50 mg)
As enzyme assays may not provide an accurate quanti- were electrophoresed on a 9% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis gel (SDS-PAGE) and transferred to polyvinylidenetation of the MAO isoforms expressed in a given tissue
difluoride membranes. The blot was incubated with a rabbit anti–MAO-[34], we determined the relative expression of MAO-A A/B polyclonal antiserum. Immunoreactive proteins were identified as
and MAO-B in MCs by Western blot analysis using an described in the Methods section. The arrows indicate proteins with
molecular masses of approximately 61 and 55 kDa, corresponding toantiserum obtained from rabbit immunized with a pep-
MAO-A and MAO-B, respectively. Data are representative of fourtide common to both MAO-A and MAO-B. The speci- experiments.
ficity of the antibody was shown by the following findings:
(a) The antiserum revealed immunoreactive bands corre-
sponding to MAO-A and MAO-B in mitochondria from
shown that, in three different cell types, the relativeyeast transformed with recombinant cDNA encoding for
expression of MAO-A and MAO-B determined byhuman placenta MAO-A and human liver MAO-B but
Western blot corresponds to that determined by enzymenot from wild-type yeasts (data not shown). (b) This
assay and measure of MAO-dependent hydrogen-perox-antiserum allowed the identification and the relative
ide generation [37]. As shown in Figure 3, Western blotquantitation of the two MAO isoforms in various human,
rabbit, and rat tissues [23, 35, 36]. (c) We have recently analysis performed in the renal cortex revealed two pro-
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teins with the apparent molecular weight expected for
MAO-A and MAO-B (approximately 61 and 55 kDa,
respectively). The relative abundance of MAO-A and
MAO-B, estimated by densitometry, was, respectively,
60 and 40% of the total amount of the MAO immunore-
active bands. These data are in agreement with previous
results obtained by enzyme assays using specific MAO-A
and MAO-B substrates. The relative amount of each
MAO isoform was different in glomeruli and isolated
MCs as compared with renal cortex. Indeed, in both
glomeruli and MCs, the approximate 61 kDa protein
corresponding to MAO-A was largely predominant
(Fig. 3). Quantitation of the relative amount of each
enzyme isoform showed that, in MCs, MAO-A repre-
sented approximately 90% of total amount of immunore-
active proteins. Thus, both Western blot analysis and
enzyme assays show that MCs contain mainly MAO-A.
The results obtained in inhibition of enzyme activity
indicate that in MCs, MAO-A is also able to metabolize
the classic MAO-B substrate PEA.
Serotonin uptake by rat mesangial cells
Monoamine oxidase A represents one of the major
metabolic pathway for serotonin degradation. As metab-
olism by mitochondrial MAO requires serotonin uptake
into the cell, we next investigated whether a SERT was
expressed in rat MCs. With this attempt, we first mea-
sured [14C]5HT uptake in isolated MCs. In order to avoid
the interference of serotonin degradation on uptake pa-
rameters, experiments were performed after MAO inac-
tivation by the irreversible inhibitor pargyline. Cell incu-
bation with 200 nm [14C]5HT led to a time-dependent
uptake that reached the maximum at 30 minutes and
remained stable at least up to 90 minutes (Fig. 4A). The
nonspecific uptake was defined in the presence of 1025 m
Fig. 4. [14C]serotonin accumulation in rat mesangial cells. (A) Timeclomipramine, a potent inhibitor of SERT, and repre- course of [14C]5HT accumulation. Total (j) and nonspecific (h)
sented 20% of the total [14C]5HT incorporation into the [14C]5HT (200 nm) accumulation were measured as described in the
Methods section. Nonspecific [14C]5HT uptake was defined in presencecells. As shown in Figure 4B, [14C]5HT was dose depen-
of 1025 m clomipramine. In order to inhibit MAOs, 1025 m pargylinedent, with a Vmax of 310 6 36 pmol/30 min/mg proteins was added to the medium 20 minutes prior to the beginning of uptake
and a Km of 5.9 6 1.4 mm. [14C]serotonin uptake was experiments. All data represent the means 6 sem of four separate
experiments. (B) Dose-dependent [14C]5HT accumulation. Cells wereinhibited by the serotonin transport inhibitors clomi-
incubated with various concentrations of [14C]5HT at 378C for 30 min-pramine and fluoxetine with IC50 of 1 6 0.4 nm and 10 6 utes in the absence (j) or in the presence of 1025 m clomipramine (h).
3.5 nm, respectively. In contrast, high concentrations of Monoamine oxidases were inhibited by 1025 m of pargyline. All data
represent the means 6 sem of seven separate experiments.the nonselective monoamine transport inhibitors b estra-
diol (IC50 3 6 0.13 mm) and disprocynium 24 (IC50 0.23 6
0.1 mm) or of the biogenic amines norepinephrine (IC50
1 mm) and dopamine (IC50 1.5 mm) were required to block performed using a polyclonal antiserum directed against
[14C]5HT uptake (Fig. 5) [38]. This inhibition profile was the SERT. Platelets that contained a SERT [28] were
similar to that previously reported in various tissues and used as a positive control. As shown in Figure 6, in both
species for the SERT. platelets and MCs, the polyclonal antiserum revealed a
peptide with an apparent molecular weight compatible
Western blot analysis of the serotonin transporter with that reported for the SERT (approximately 70 kDa)
expressed in mesangial cells [28]. Taken together, uptake experiments and Western
We definitively confirmed the expression of a SERT blots show that MCs contain a SERT responsible for
intracellular serotonin accumulation.in MCs by Western blots analysis. Experiments were
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dent release of [14C]5HT metabolites in the extracellular
medium (Fig. 7). These findings indicate that the de-
crease in intracellular radioactivity was related to the
extracellular release of [14C]5HT metabolites generated
by MAO. These data show that after intracellular trans-
port, serotonin is inactivated by MAO, and its metabo-
lites are released in extracellular medium.
Effect of monoamine oxidase inhibition by pargyline
on mesangial cell proliferation
As shown in Figure 8, serotonin induced a highly sig-
nificant dose-dependent stimulation in BrdU incorpora-
tion, which reached the maximum (170 6 11% increase)
at 500 to 1000 nm. When experiments were performed
in the presence of 10 mm pargyline, the serotonin-induced
cell proliferation was enhanced significantly. A maximal
44 6 8% increase was observed in the presence of 100Fig. 5. Inhibition of [14C]5HT uptake. Mesangial cells were incubated
with [14C]5HT (200 nm) in the absence or presence of the different nm serotonin when compared with the effect induced by
inhibitors. The curves represent the means 6 sem of two to four separate serotonin alone. No effect of pargyline alone on BrdU
experiments. Symbols are: (j) clomipramine; (h) fluoxetine; (d) dis-
incorporation was observed.procynium 24; (s) b-estradiol; (m) norepinephrine; (n) dopamine.
DISCUSSION
Monoamine oxidase A and B are widely distributed
in renal cortex and medulla. Most of the studies on renal
MAOs concerned the proximal tubule. In this segment
of the nephron, MAO-A is the predominant isoform,
and it is involved in the regulation of the amount of
dopamine and serotonin synthesized and released by the
epithelial tubular cells [39, 40]. In the other renal cells,
which are unable to synthesize dopamine and serotonin,
Fig. 6. Western blot of serotonin transporter (SERT). Crude extracts intracellular transport systems are necessary to allow the
from rat mesangial cells and human platelets were electrophoresed
substrate degradation by mitochondrial MAOs. Cur-on a 8% SDS-PAGE gel and transferred to polyvinylidene difluoride
membranes. The blot was immunoblotted with SERT antibody (Santa rently, very little is known concerning the expression
Cruz Biotechnology). Immunoreactive proteins were identified as de- and function of biogenic amines transport systems and
scribed in the Methods section. The arrow indicates immunoreactive
MAO in the different portions of the nephron.protein with molecular mass of approximately 70 kDa. Data are repre-
sentative of three independent experiments. In this study, we show the expression of MAOs and
a SERT in MCs. As shown by enzyme assays and West-
ern blot analysis, MAO-A is the predominant isoform
expressed in MCs and represents approximately 90% of
Intracellular metabolism of serotonin by the total MAO population. In contrast, the fact that
rat mesangial cells MAO-B was significantly decreased in MCs as compared
Next, we investigated whether serotonin, after the up- with whole renal cortex indicates that this enzyme iso-
take into MCs, was metabolized by MAOs. With this form is mainly located in another cell type. MAO-A
attempt, we measured intracellular [14C]5HT content and and MAO-B are generally considered specific for the
the release of serotonin metabolites in the extracellular degradation of serotonin and PEA, respectively. Surpris-
medium with or without irreversible MAO inhibition. ingly, we found that in MCs, MAO-A is able to metabo-
[14C]Serotonin uptake experiments performed in the lize PEA with an apparent affinity constant similar to
presence of the irreversible MAO inhibitor pargyline that reported for PEA degradation by MAO-B [21]. In
showed that [14C]5HT accumulated into MCs in a time- renal cortex, the ability of MAO-A to metabolize the
dependent manner, and [14C]5HT metabolites were MAO-B substrate seems to be specific of MCs. Indeed,
slightly detectable in the extracellular medium (Fig. 7). enzyme assays performed in whole renal cortex and iso-
In the absence of MAO inhibition, the amount of intra- lated proximal tubules showed that MAO-A and
cellular [14C]5HT significantly decreased at the different MAO-B display a classic substrate specificity (Copin et
al, unpublished data) [21, 24]. It is noteworthy that, astime tested, and we observed a concomitant time-depen-
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Fig. 7. Effect of monoamine oxidases on
[14C]5HT accumulation in rat mesangial cells.
(A) Time course of intracellular [14C]5HT
accumulation. Specific accumulation of [14C]-
5HT (200 nm) was measured with (j) or with-
out (n) the monoamine oxidase inhibitor par-
gyline (1025 m). Specific transport was defined
as the fraction of total uptake inhibited by
1025 m of clomipramine. (B) Time course of
extracellular [14C]5HT metabolites accumu-
lation. [14C]Serotonin metabolites measured
with (j) or without (n) the monoamine oxi-
dase inhibitor pargyline (1025 m). Experiments
were performed as described in the Methods
section. All data represent the means 6 sem
of four separate experiments. *P , 0.05;
**P , 0.01; ***P , 0.001.
those reported for SERTs identified in the central ner-
vous system and in some peripheral cells or organs [25,
27, 28, 41]. This transporter displays a relative selectivity
for serotonin as high concentrations of two other endo-
genous amines, norepinephrine and dopamine, were
required to inhibit serotonin uptake. As shown by up-
take experiments performed without MAO inhibition,
MAO-A of MCs plays a major role in the degradation
of extracellular serotonin. Indeed, in absence of the irre-
versible MAO inhibitor pargyline, we observed a con-
comitant decrease in intracellular serotonin accumula-
tion and the release of serotonin metabolites in the
extracellular medium. These results show that, as pre-
viously reported for presynaptic terminals and glial cells,
SERT and MAO-A in MCs may play a critical role inFig. 8. Serotonin-dependent BrdU incorporation into mesangial cell
(MC) entry into the S phase in the presence ( ) or absence (j) removing extracellular serotonin.
of the monoamine oxidase inhibitor pargyline. Quiescent MCs were The potential relevance of SERT and MAO-A in thestimulated with increasing doses of serotonin in the absence (j) and
regulation of MC functions is supported by our experi-the presence of pargyline ( ). Results are means 6 sem of four distinct
experiments. *P , 0.05; **P , 0.01. ments on the effect of MAO inactivation on serotonin-
mediated cell proliferation. Indeed, we showed that
irreversible MAO inhibition significantly increased sero-
tonin-mediated BrdU incorporation into MCs. It is note-observed in MCs, the rat heart MAO-A is also able to
worthy that the effect of MAO inactivation was maximalmetabolize PEA (abstract; Guimaraes and Soares-Da-
at 50 and 100 nm serotonin, concentrations close to thoseSilva, Biochem Soc Trans 25:S622, 1997). These data
found in plasma of diabetic patients [42, 43]. Serotoninindicate that the classic substrate specificity of MAO-A
is one of the factors involved in the development andand MAO-B is not absolute and may depend on cell-
progression of glomerulonephritis at least through twotype–specific factors.
distinct mechanisms: the proliferation of MCs and theThe demonstration of the expression of MAO-A in
production of type IV collagen [44]. It is generally ac-MCs suggested a potential role of this enzyme in the
knowledged that the serotonin concentration in glomer-degradation of glomerular serotonin. This possibility has
uli depends mainly on platelet release. In contrast, ourbeen further supported by our results showing the pres-
results show that serotonin concentration and functionence of a SERT in MCs. To date, the expression of a
in glomeruli may be also regulated by its uptake andspecific serotonin transport system in kidney was un-
degradation by MCs. Therefore, SERT and MAO-Aknown. The studies of serotonin uptake and Western
may play a protective role against the deleterious effectsblot analysis showed that the SERT in MCs displays
pharmacological and biochemical properties similar to of serotonin on glomeruli, and it is conceivable that their
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tion of GTPase-activating protein with mitogenic action of seroto-impairment may be involved in abnormalities of MC
nin. Am J Physiol 272:C223–C230, 1997
function under pathological situations. 15. Soares-Da-Silva P, Pinto-do-O PC, Bertorello AM: Antagonis-
tic actions of renal dopamine and 5-hydroxytryptamine: IncreaseIn conclusion, the demonstration of the coexpression
in Na1,K1-ATPase activity in renal proximal tubules via activationof a SERT and MAO-A in MCs opens new perspectives
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